In	Monthly Themes	Special Days/Holidays	Date	Twitter Copy	LinkedIn Copy	Photo /Video Asset to Accompany Post	URL	Paid Support (Amount/Flight Period)
Thought Leadership			Monday, May 01, 2023	Our #DiversitAb™ platform revolutionizes the way we fight disease. Its ability to produce large scale fully-human immunoglobulins #higGs across untiple modalities is changing the game in antibody development. Learn more: [LINK] #SABBio #AntibodyDevelopment	Our DiversitAb <sup>™</sup> platform is changing the game in antibody development with its ability to produce large scale human high-titer, high-widity fully- human immunoglobulins #higGs across multiple modalities. It represents a unique targeted higG discovery and product development engine that can tackle complex diseases with multiple dysregulated pathways. Join us in the revolutionizing the waye fight disease with our innovative platform: [LINK] #SABBio #DiversitAb #AntibodyDevelopment	CARACTERISTIC	https://www.sab.bio/sab-science/	\$25 Twitter \$75 Linkedin
Industry News			Tuesday, May 02, 2023					
Platform Innovation			Wednesday, May 03, 2023	HOLD for ISIRV Conference presentation	HOLD for ISIRV Conference presentation	HOLD for ISIRV Conference presentation	Presentation Page	\$25 Twitter \$75 LinkedIn
Company/PR Updates			Thursday, May 04, 2023					
				#SABBio's SAB-142 has shown promising results in pre- clinical trials, offering a safer, fully-human immunoglobulin (hgG) alternative to currently available #therapeutics for Type 1 Diabetes. Learn more about how we're innovating to improve lives! [LINK] #TID #Immunology #Biopharma	SAB Biotherapeutics is dedicated to revolutionizing the treatment of serious autoimmune diseases like Type 1 Diabetes through the development of innovative therapies. Our pre-clinical program, SAB- 142, has demonstrated highly promising results in both preclinical safety and in vivo immunomodulatory activity. These results have enabled us to move forward with confidence towards IND filing. What sets SAB-142 apart from current animal- derived biologics under investigation for TiD is that it offers a fully-human alternative. This means that it provides a safer foundation for re-dosing while avoiding major immune reactions such as serum sickness. Given that millions of people worldwide are affected by TID, we believe that this groundbreaking treatment has the potential to make a significant impact in the future of autoimmune disease treatment. Join us as we continue to push the boundaries of movation in therapeutics development to improve the lives of those affected by TID and other autoimmune diseases. Learn more about SAB-142 and our work at SAB Biotherapeutics: [UNK] #SABBio #TID #Innovation #Therapeutics #Immunology #Biopharma	<image/> <section-header></section-header>	SAB 142 Page / <u>https://www.sab.bio/sab- science/</u>	\$25 Twitter \$75 LinkedIn
			Saturday, May 06, 2023					
	]		Sunday, May 07, 2023					
			Monday, May 08, 2023	#DiversitAb is a game-changer for the field of #antibody production. We're working to advance this technology to produce potent #humanigG across multiple modalities. Learn more: [LINK] #SAbBio	Our human immunoglobulins (higG) represent the first time that fully-human antibodies, produced from hyperimunization of SAB's patented TcBorine, allow targeting to complex diseases with multiple dysregulated pathways to be fully explored as potent immunotherapies that can target multiple different targets and modes of action all in the same regulated product. This is the first scalable technology that mimics the natural way humans fight disease through production of higG: [LINK] #SABBio #Immunoglobulin #Therapeutics #BiologicalTechnology	Benerus Polycional Antibody Development Human b6 antibodes alow targeting to complex diseases with multiple dysregulated pathways.	https://vimeo.com/794173009	\$25 Twitter \$75 LinkedIn
	]		Tuesday, May 09, 2023					

Wednesday, May 10, 2023 Thursday, May 11, 2023	HOLD for Eddie at Sidoti Conference	HOLD for Eddie at Sidoti Conference	HOLD for Eddie at Sidoti Conference	HOLD for Eddie at Sidoti Conference	\$25 Twitter \$75 Linkedin
Thursday, May 11, 2023					
	May is #OlderAmericansMonth and at #SABBio, we take this opportunity to honor & celebrate the contributions of older Americans to our society. As a #biopharma company, we are committed to advancing our human immunoglobulis [hig63] to provide effective treatment options for diseases affecting the lives of older Americans. Learn more: [LINK]	Did you know that May is recognized as Older Americans Month by the @US Department of Health and Human Services? At SAB Biotherapeutics, we take this opportunity to honor and celebrate the contributions of older Americans to our society. We are also reminded of the challenges facing this population, especially in terms of health. Many of the diseases our platform is aimed at, such as C. Diff with SAB-195, Type 1 Diabetes with SAB-142, and COVID with SAB-185, severely affect older Americans. We recognize the importance of addressing these challenges and improving health outcomes for this vulnerable population. As a biopharmaceutical company, we are committed to advancing our human immunoglobulins (higGs) to provide effective treatment optics of older Americans and improve health outcomes for all. Let us take this opportunity for effect on the contributions of our older population and recommit ourselves to advancing medical research and development for their benefit: [UNN] #DIderAmericansMonth #SABBIO #HumanImmunoglobulins #Immunology #Therapeutics	AND RESERVANT	https://acl.gov/oam/2023/older-americans- month-2023	N/A
Saturday, May 13, 2023					
Sunday, May 13, 2023					
Monday, May 15, 2023	HOLD for Earnings Release	HOLD for Earnings Release	HOLD for Earnings Release	HOLD for Earnings Release	\$25 Twitter \$75 LinkedIn
Tuesday, May 16, 2023					
Wednesday, May 17, 2023	#DiversitAb uses the latest scalable technology to produce human immunoglobulin #hlgG antibodies in a way that minisc the human immune response. With the potential to target multiple modes of action, learn how our innovative platform is leading the way in fully-human antibody therapy: [LINK] #SABBio	Our DiversitAb <sup>™</sup> platform is the first scalable technology that mimics the natural way humans fight disease through the production of human immunoglobulins (higGs). Our innovative platform allows for the development of powerful, fully-human immunoglobulin treatment sthat can address multiple dysregulated pathways, multiple targets, and multiple epitopes all at once. This means that patients could potentially benefit from having a controlled and infinite source of human antibodies without the need for human donors. The potential benefits of this technology are tremendous, and we are proud to be at the forefront of antibody development. Join us in our mission to revolutionize the field of therapeutics by changing the game with our DiversitAb <sup>™</sup> platform. Learn more about our groundbreaking work at SAB Biotherapeutics and how our DiversitAb <sup>™</sup> platform (LINK] #SABBiotherapeutics #DiversitAb #Therapeutics #Innovation #AntibodyDevelopment	Direatures Direatures Direatures Dur platform can consistent supply of fully-human supply of fully-human suppl	https://www.sab.bio/sab-science/	\$25 Twitter \$75 LinkedIn

Image: Set in the set in	
Saturday, May 20, 2023   Saturday, May 20, 2023   Saturday, May 21, 2023<	
Saturday, May 20, 2023   Saturday, May 21, 2023<	
SAB Biotherapeutics is leading the charge in minorable science in fractional disease in the constant of the same intermunoglobulin (hig6) antibody therapy high antibody high antibody therapy high antibody therapy high antibody therapy high antibody therapy high antibody high antibody therapy high antibody therapy high antibody therapy high antibody high antin the anthigh antin the potential and and antipartic high antin t	
Wednesday, May 24, 2023 Image: State of the state	
Friday, May 26, 2023 Friday, May 26, 2023	

Saturday, May 27, 2023				
Sunday, May 28, 2023				
Our groundbreaking therapy, #SAB142, is the first fully- human anti-thymocyte therapeutic that can be administered multiple times without inducing unwanted immune reactions. With potential benefits for millions living with #Type1Diabetes, we're excited to continue its development: [LINK] #SABBio #Immunotherapy #T1D	We are honored to be at the forefront of Type 1 Diabetes research and development. Our innovative SAB-142 program offers a fully-human anti- thymocyte hpAB therapeutic that can be administered multiple times without causing immune-related adverse reactions. In our GLP-tox study, SAB-142 induced transient lymphodepletion, confirming its mechanism of action, and potentially providing an opportunity for optimized dosing regimens. We're excited about the potential of SAB-142 to make a significant impact on the lives of millions of patients with Type 1 Diabetes. Join us in advancing this breakthrough therapy and stay updated on our other developments: [LINK] #SABBio #T1D #type1diabetes #biotech #immunology #biopharma #SAB142	SAB DEIOTHERAPEUTICS SAB BIOTHERAPEUTICS Wery unique has the ability to deliver for very complex diseases."	SAB 142 Page / <u>https://www.sab.bio/sab- science/</u>	\$25 Twitter \$75 LinkedIn
Tuesday, May 30, 2023				
#SABBio transgenic cows carry the entire human IgG heavy Wednesday, May 31, 2023 and light chain loci, making them the only animal capable producing fully-human antibodies. Read more: [LINK] #Therapeutics #Immunology #Biopharma		Ar bioteness of the sector of	https://www.sab.bio/sab-science/	\$25 Twitter \$75 Linkedin